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Abstract: The Liver Imaging Reporting and Data System (LI-RADS®) is a comprehensive 
system for standardizing the terminology, technique, interpretation, reporting, and data collection 
of liver observations in individuals at high risk for hepatocellular carcinoma (HCC). LI-RADS 
is supported and endorsed by the American College of Radiology (ACR). Upon its initial release 
in 2011, LI-RADS applied only to liver observations identified at CT or MRI. It has since been 
refined and expanded over multiple updates to now also address ultrasound-based surveillance, 
contrast-enhanced ultrasound for HCC diagnosis, and CT/MRI for assessing treatment response 
after locoregional therapy. The LI-RADS 2018 version was integrated into the  HCC diagnosis, 
staging, and management practice guidance of the American Association for the Study of Liver 
Diseases (AASLD). This article reviews the major LI-RADS updates since its 2011 inception 
and provides an overview of the currently published LI-RADS algorithms.
Keywords: LI-RADS, v2018, CT, MRI, CEUS, US, HCC, liver imaging, reporting, cirrhosis
Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and 
the third leading cause of cancer-related mortality worldwide.1,2 Early detection of 
HCC is important as it has been shown to improve overall survival, particularly when 
patients are able to receive potentially curative therapy such as resection or orthotopic 
liver transplantation.3 The diagnosis of HCC may be made noninvasively by imaging 
findings alone, often without the need for percutaneous biopsy, in patients who are 
considered to be at high risk for HCC.4–6 Consequently, radiologists must be accurate 
in their interpretation and reporting of liver imaging so that therapy may be rendered to 
patients with HCC in an appropriate and timely manner. The Liver Imaging Reporting 
and Data System (LI-RADS®) was conceived to address this need. Free-text reports 
often contain vague wording and may vary based on the radiologist practice setting 
and experience level. This, in turn, may lead to confusion among clinical teams respon-
sible for the management of patients at risk for or with HCC. LI-RADS provides a 
standardized lexicon, strict diagnostic criteria, an easy-to-follow diagnostic algorithm, 
and reporting guidelines to improve the consistency and clarity of radiologist inter-
pretation and reporting.
One benefit of LI-RADS is improved communication between radiologists and 
clinicians. According to the LI-RADS diagnostic algorithm, each liver observation in a 
patient at high risk for HCC is assigned a category (from LR-1 to LR-5) reflecting the 
relative likelihood of being HCC.7 Interrater agreement for LI-RADS categorization is 
substantial, and structured LI-RADS reporting has been shown to improve reporting 
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consistency.8,9 These studies were largely conducted among 
expert radiologists at high-volume centers, and further data 
among community radiologists are needed. LI-RADS is sup-
ported and endorsed by the American College of Radiology 
(ACR) and in 2018 was integrated into the American Asso-
ciation for the Study of Liver Diseases (AASLD) guidance 
statement for HCC.1
In this article, we review the expansions and updates of 
LI-RADS since its 2011 inception, including the LI-RADS 
ultrasound surveillance algorithm, the LI-RADS CT/MRI 
diagnostic algorithm (Figure 1), the LI-RADS contrast-
enhanced ultrasound (CEUS) diagnostic algorithm, and the 
LI-RADS CT/MRI treatment response algorithm. Major 
changes to the LI-RADS v2018 CT/MRI diagnostic algo-
rithm are highlighted, and a glimpse into future directions 
of LI-RADS is provided.
Overview of major Li-RADS updates
LI-RADS is a dynamic system, with updates released regu-
larly to incorporate user feedback, expanding knowledge, and 
Figure 1 Li-RADS CT/MRi diagnostic algorithm and table v2018.
Notes: Reproduced with permission  from American College of Radiology. Liver imaging Reporting and Data System version 2018 core. Available from: https://www.acr.
org/Clinical-Resources/Reporting-and-Data-Systems/Li-RADS.16
Abbreviations: ACR, American College of Radiology; APHe, Arterial phase hyperenhancement; HCC, hepatocellular carcinoma; Li-RADS, Liver imaging Reporting and Data 
System; LR-NC, LR-noncategorizable; Tiv, tumor in vein.
Untreated observation without pathologic proof in patient at high risk for HCC
Otherwise, use CT/MRI diagnostic table below
If cannot be categorized due to image degradation or omission
If definitely benign
If probably benign
If probably or definitely malignant but not HCC specific (eg, if targetoid)
If intermediate probability of malignancy
If probably HCC
If definitely HCC
APHE
Observation size (mm)
• Enhancing “capsule”
• Nonperipheral “washout”
• Threshold growth
Observations in this cell are categorized based on one additional major feature:
• LR-4 – if enhancing “capsule”
• LR-5 – if nonperipheral “washout” OR threshold growth
Count additional major features:
CT/MRI diagnostic table
LR-NC
LR-1
LR-2
LR-3
LR-4
LR-5
No APHE
<20
None
One
≥Two
LR-3 LR-3 LR-3 LR-3 LR-4
LR-3 LR-4 LR-4 LR-4LR-5
LR-4
LR-5
LR-5
LR-4 LR-4 LR-4 LR-5 LR-6
<10 10–19≥20 ≥20
Nonrim APHE
LR-M
If definite TIV LR-TIV
CT/MRI LI-RADS® v2018 CORE
If unsure about the presence of any major feature: characterize that feature as absent
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technological advances.10 The major changes to LI-RADS 
for each update are enumerated in the following sections.
Li-RADS v2011
The initial version of LI-RADS was released in 2011 with 
a standardized lexicon and five major categories for clas-
sifying observations in the liver: LR-1 (definitely benign), 
LR-2 (probably benign), LR-3 (intermediate probability for 
HCC), LR-4 (probably HCC), and LR-5 (definitely HCC).11
Li-RADS v2013
The first major update to LI-RADS was released in 2013. It 
introduced a diagnostic table and imaging atlas. Modifica-
tions to the LR-5 category were made to achieve congruency 
between the Organ Procurement and Transplantation Net-
work (OPTN) Class 5 and LR-5. Three new categories were 
formed: LR5 treated was congruent with the OPTN Class 5T 
category, OM (other malignancy) to account for malignant 
entities other than HCC that may occur in the liver, and LR5V 
for definitely HCC with the presence of tumor in vein (TIV).
Li-RADS v2014
The 2014 LI-RADS update introduced material on hepa-
tobiliary agents. The diagnostic algorithm was modified 
and some of the terminology was simplified. In particular, 
the designations A (≤19 mm) and B (≥20 mm), which split 
LR-4 and LR-5 categories based on observation size, were 
removed.12 A split cell was introduced into the algorithm for 
10–19 mm observations with arterial phase hyperenhance-
ment (APHE) and one additional major feature for HCC; 
observations in this cell with “washout” and visibility on 
antecedent screening ultrasound were assigned LR-5us as 
per the 2011 AASLD guidelines,13 observations in this cell 
meeting criteria for threshold growth were assigned LR-5g 
for congruency with OPTN Class 5A-g,14 and all other obser-
vations in this cell were assigned LR-4. OM was changed 
to LR-M (probably or definitely malignant, but not specific 
for HCC), in  recognition that corresponding lesions were 
not always an “other malignancy” but could be HCC and 
sometimes even could be benign. The lexicon and atlas were 
refined and expanded.
Li-RADS v2017
LI-RADS v2017 added new algorithms for US surveillance, 
CEUS diagnosis, and CT/MRI treatment response assess-
ment. The category LR-noncategorizable (LR-NC) was 
added to describe observations that cannot be categorized 
due to image degradation or omission. LR-5V was renamed 
LR-TIV in recognition that a minority of TIV observations 
represent non-HCC malignancy.15 Additionally, the threshold 
growth definition was modified, and new explicit criteria for 
LR-M were introduced.
Li-RADS v2018
The 2018 update achieved a major milestone by unifying 
LI-RADS and AASLD. The process of unification required 
revision of the LR-5 category (Table 1). In particular, the 
requirement for visibility at antecedent US for LR-5 des-
ignation for 10–19 mm observations with nonrim APHE 
and “washout” was removed. The LR-5 nomenclature was 
simplified by removal of the -us and -g qualifiers. Addition-
ally, the LI-RADS definition of threshold growth was also 
simplified to match that of the United Network for Organ 
Sharing and the Organ Procurement and Transplantation 
Network (UNOS-OPTN).16
US Li-RADS
Overview
Ultrasound is the most commonly used method for surveil-
lance in patients at risk for HCC. It has the benefit of being 
a noninvasive, accessible, safe, and low-cost screening tool 
for HCC. In a meta-analysis of 15 scientific studies on HCC 
surveillance in patients with cirrhosis, sonography had a 
pooled sensitivity of 47% for early-stage cancer detection.17 
Table 1 Major changes to CT/MRi Li-RADS v2018
Major changes to CT/MRI LI-RADS v2018*
Type of change Description
Substantive Requirement of visibility on antecedent US for LR-5 designation of 10–19 mm observations with nonrim APHe and 
“washout” removed
Substantive OPTN definition of threshold growth adopted: ≥50% size increase of a mass in ≤6 months
Nomenclatural -us removed as LR-5 qualifier
Nomenclatural -g removed as LR-5 qualifier
Note: *No changes made to CeUS Li-RADS or ultrasound Li-RADS.
Abbreviations: APHe, arterial phase hyperenhancement; CeUS, contrast-enhanced ultrasound; Li-RADS, Liver imaging Reporting and Data System; OPTN, Organ 
Procurement and Transplantation Network.
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Two prospective, randomized controlled trials in East Asia 
have shown that ultrasound surveillance decreased HCC-
related mortality by 31%–37%.18,19 However, until now, there 
has been a lack of standardization of ultrasound interpretation 
and reporting. An ACR-endorsed working group developed a 
new LI-RADS algorithm specific to the interpretation of HCC 
screening and surveillance by ultrasound (US LI-RADS).20 
Standardization of ultrasound technique and radiology report-
ing in high-risk individuals should improve communication 
between physicians and unify surveillance algorithms at dif-
ferent institutions, as accomplished by the CR/MRI LI-RADS 
diagnostic algorithm.20 The appropriate patient population 
for the application of US LI-RADS is listed in Table 2. The 
primary at-risk population includes patients with cirrhosis 
from any etiology. The benefit of surveillance is unknown 
in adults with nonalcoholic steatohepatitis or hepatitis C 
infection in the absence of cirrhosis; however, these patients 
may be included in surveillance populations depending on 
regional practice guidelines. Patients with decompensated 
Child–Pugh C cirrhosis are excluded due to limited life 
expectancy unless the patient is a liver transplant candidate; 
however, the best strategy for HCC surveillance in transplant 
candidates is currently unclear.
The US LI-RADS algorithm includes two components: 1) 
an ultrasound category (Figure 2) and 2) visualization score 
(Figure 3). No changes to US LI-RADS were introduced 
in 2018.
Ultrasound category
The study category, which is applied to the entire study as 
opposed to individual observations, determines management 
and potential need for further characterization of observations 
with a contrast-based study.20 The three categories are; 1) 
US-1: Negative, defined as no suspicious sonographic find-
ings of HCC that warrant further evaluation. This includes the 
absence of any focal lesions or the presence of only definitely 
benign findings, such as focal fatty sparing, simple cyst, 
or previously confirmed hemangioma. The recommended 
management for category 1 is continued routine surveil-
lance every 6 months.20,21 2) US-2: Subthreshold, defined 
as the presence of one or more focal lesions, all <10 mm, 
that are not definitely benign. The recommended manage-
ment of US-2 involves close follow-up with short-interval 
ultrasound every 3–6 months to identify growth beyond the 
1 cm threshold, in which case, further characterization with 
a contrast-based study is warranted.20,21 If an observation 
in an US-2 study is stable in size for 2 years or greater, the 
patient can return to routine 6-month surveillance. 3) US-3: 
Positive, defined as the presence of one or more observa-
tions ≥10 mm and not definitely benign. Such observations 
warrant further characterization with contrast-enhanced 
imaging. Examples include solid nodules ≥10 mm of any 
echogenicity (Figure 4), a new thrombus in a vein (whether 
considered bland thrombus or TIV), or focal parenchymal 
distortion ≥10 mm in size (Figure 5). The latter indicates 
the possibility of diffuse or infiltrative subtype of HCC, and 
it is defined by one or more of the following sonographic 
findings: ill-defined area of heterogeneity, refractive edge 
shadowing, loss of normal hepatic architecture, and distortion 
of vessels. The management for US-3 is further characterized 
with multiphase contrast-enhanced CT, MRI, or CEUS.20,21
visualization score
The visualization score is assigned to each examination based 
on technical quality and study limitations and conveys the 
expected sensitivity of the examination for detection of liver 
lesions. Multiple extrinsic and intrinsic factors can affect the 
quality of ultrasound visualization of the liver parenchyma 
including the patient body habitus, obscuration of the liver 
Table 2 The inclusion and exclusion criteria of Li-RADS (CT, 
MRi, CeUS, and ultrasound surveillance)
Surveillance ultrasound target population
•	 Inclusion: 
	 Adults with cirrhosis of any cause
	 Subsets of adult patients with chronic HBv infection, even in 
the absence of cirrhosis
	 Asian male hepatitis B carriers over age 40 years
	 Asian female hepatitis B carriers over age 50 years
	 Hepatitis B carrier with family history of HCC
	 African or North American blacks with hepatitis B
•	 Exclusion:
	 Child–Pugh C cirrhosis, unless patient is a transplant candidate
•	 Population in which benefit of surveillance is uncertain: 
	 Adults with NASH but without cirrhosis
	 Adults with chronic hepatitis C without cirrhosis
Diagnostic population for LI-RADS (CT, MRI, and CEUS)
•	 Inclusion: 
	 Adults with cirrhosis
	 Chronic hepatitis B
	 Current or prior HCC including adult liver transplantation 
candidates and patients posttransplant
•	 Exclusion: 
	 Cirrhosis due to vascular disorder or congenital hepatic 
fibrosis
	 Pediatric patients
Notes: Target populations for screening and surveillance and target population 
for diagnostic imaging with CT, MRi, or CeUS. Guidelines based on the American 
Association for Study of Liver Diseases (AASLD).1
Abbreviations: CeUS, contrast-enhanced ultrasound; HCC, hepatocellular 
carcinoma; HPv, hepatitis B virus; Li-RADS, Liver imaging Reporting and Data 
System; NASH, nonalcoholic steatohepatitis.
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by lung or bowel gas, a patient’s inability to hold their breath 
or hold still, and hepatic parenchymal heterogeneity or sound 
attenuation due to fibrosis/cirrhosis or steatosis.20 The three 
scores are as follows: 1) Visualization A: No or minimal limi-
tations, where the liver is visualized in its near entirety and 
there is little or no compromise on the sensitivity of detection 
of parenchymal masses. 2) Visualization B: Moderate limita-
tions, which may decrease sensitivity of detection of small 
masses. Examples include moderate hepatic heterogeneity or 
difficult visualization of small portions of the liver. 3) Visual-
ization C: Severe limitations, which may markedly lower the 
sensitivity for detection of liver observations. These limita-
tions include severe parenchymal heterogeneity,  substantial 
beam attenuation, which results in nonvisualization of large 
portions of the liver and diaphragm, or other factors that 
limit visualization of >50% of the liver or diaphragm.20,21 
It is important to note that currently the visualization score 
does not impact management recommendations – this is 
an active area of research, and as data and experience are 
collected, future versions of US LI-RADS may incorporate 
the visualization score into management recommendations.
Li-RADS diagnostic population
The criteria for the population on which LI-RADS can 
be applied for diagnosis, as opposed to surveillance, was 
introduced with v2017 and is carried over unchanged in 
Figure 2 US Li-RADS US category.
Notes: Reproduced with permission from American College of Radiology. Ultrasound Li-RADS v2017. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/
Li-RADS/Ultrasound-Li-RADS-v2017.21
Abbreviations: ACR, American College of Radiology; HCC, hepatocellular carcinoma; Li-RADS, Liver imaging Reporting and Data System; US, ultrasound.
Negative
US-2
US-3
US-1
Subthreshold
Positive
Category Concept
US-1
Negative No US evidence of HCC
US-2
Subthreshold 
Observation(s) detected that may
warrant short-term US surveillance
Observation(s) detected that may
warrant contrast-enhanced imaging
Definition
No observation OR only definitely benign 
observation(s) 
Observation(s) <10 mm in diameter, not
definitely benign
Observation(s) ≥10 mm in diameter, not 
definitely benign OR new thrombus in vein
US-3
Positive
Figure 3 US Li-RADS visualization score.
Notes: Reproduced with permission from American College of Radiology. Ultrasound Li-RADS v2017. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/
Li-RADS/Ultrasound-Li-RADS-v2017.21
Abbreviations: ACR, American College of Radiology; Li-RADS, Liver imaging Reporting and Data System.
A No or minimal limitations
B
C
Moderate limitations
Severe limitations
Score Concept
A. No or
minimal
limitations 
Limitations if any are
unlikely to meaningfully
affect sensitivity 
B. Moderate
limitations
Limitations may obscure
small masses 
C. Severe
limitations  
Limitations significantly
lower sensitivity for focal
liver lesions 
Examples
Liver homogeneous or minimally heterogeneous
Minimal beam attenuation or shadowing
Liver visualized in near entirety
Liver moderately heterogeneous
Moderate beam attenuation or shadowing
Some portions of liver or diaphragm not visualized
Liver severely heterogeneous
Severe beam attenuation or shadowing
Majority (>50%) of liver not visualized
Majority (>50%) of diaphragm not visualized 
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v2018. The inclusion criteria includes patients with cir-
rhosis, patients with chronic hepatitis B viral infection, and 
patients with current or prior HCC, including adult liver 
transplantation candidates and patients posttransplant.15,22 
The exclusion criteria include cirrhosis due to either vascular 
disorders or cirrhosis due to congenital hepatic fibrosis.22–24 
Vascular disorders leading to cirrhosis often have a large 
number of arterialized benign nodules resembling HCC, 
which can cause diagnostic confusion and reduce the diag-
nostic specificity. LI-RADS was not validated for use with 
the pediatric population, and as such, patients under 18 years 
old are excluded from the LI-RADS diagnostic population.15
CT/MRI LI-RADS
CT/MRi Li-RADS diagnostic categories
Although no new categories have been introduced in version 
2018, the LR-5 category was modified to be congruent with 
the AASLD practice guidelines. A brief review of the major 
imaging features, ancillary imaging features, and categories 
of LI-RADS is provided below, highlighting the modifica-
tions of the LR-5 category in version 2018.
Major imaging features used in CT/MRi 
Li-RADS
Five major imaging features are used to assign LR-3 through 
LR-5 categories for observations seen in patients at risk for HCC. 
Their presence should be unequivocal to maintain high specific-
ity for HCC.25 The goal of standardization of definitions of these 
features is to encourage consistent application and interpretation, 
ultimately resulting in more consistent patient care, clearer educa-
tion, and more rigorous and reproducible research.25
Nonrim APHe
This feature is defined as nonrim enhancement of an obser-
vation in the arterial phase that is unequivocally greater 
than the background liver tissue (Figure 6). It reflects the 
process of angiogenesis, which is a key component of HCC 
pathogenesis.26 This feature is considered present if either 
the entire observation or only a portion is hyperenhancing. 
The LR-5 category can only be assigned to observations 
with unequivocal nonrim APHE (and not simply vascular 
shunts with no correlation on other sequences; these are 
considered LR-2 or -3 observations), which is consistent 
with UNOS and OPTN criteria.27 Rim APHE is not a major 
feature of HCC, but would instead prompt assigning the 
LR-M category.27
Nonperipheral “washout”
The term nonperipheral washout appearance or “washout” 
is a perceived temporal reduction in enhancement of an 
observation relative to surrounding liver parenchyma from 
Figure 4 US Li-RADS Category 3 observation in a 59-year-old male with hepatitis 
C cirrhosis undergoing US surveillance.
Notes: Sagittal US image shows a 3.6 cm solid hypoechoic observation with 
lobulated margins in segment 6. This patient requires contrast-based studies; CeUS, 
CeCT, or CeMRi to further characterize the lesion.
Abbreviations: CeUS, contrast-enhanced ultrasound; Li-RADS, Liver imaging 
Reporting and Data System; US, ultrasound.
Figure 5 US Li-RADS Category 3 observation in a 70-year-old female with 
cryptogenic cirrhosis undergoing US surveillance. 
Notes: Transverse US image shows a large area of heterogeneity (arrows) 
distinctive from background liver, shown to represent an HCC with infiltrative 
appearance on a diagnostic CeUS (not shown).
Abbreviations: CeUS, contrast-enhanced ultrasound; HCC, hepatocellular 
carcinoma; Li-RADS, Liver imaging Reporting and Data System; US, ultrasound. 
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an earlier to later phase.28 This feature may be applied to 
any enhancing observation even in the absence of APHE.16 
Although not fully understood, “washout” has been attributed 
to the lower extracellular volume of a tumor compared with 
background liver, which manifests as relative hypoenhance-
ment in the postarterial extracellular phases. “Washout” 
can be assessed in the portal venous or delayed phase if an 
extracellular contrast agent is administered with MRI or CT. 
When using gadoxetate disodium, “washout” can only be 
assessed on the portal venous phase and cannot be reliably 
evaluated on the transitional or hepatobiliary phases because 
the background liver is changing as the hepatocytes take 
up the contrast medium.29 One of the most reliable imag-
ing hallmarks of HCC is the presence of nonrim APHE in 
combination with nonperipheral washout appearance.30 As 
opposed to nonperipheral “washout,” peripheral washout is 
characteristic of intrahepatic cholangiocarcinoma (iCCA) and 
other non-HCC malignancies, hence is used as a criterion for 
assigning an LR-M category.15,27
enhancing “Capsule”
“Capsule appearance” or “capsule” is defined as a uniform, 
sharp, smooth rim of hyperenhancement around most or 
all of an observation that is unequivocally thicker or more 
conspicuous than fibrotic tissue surrounding cirrhosis-related 
background liver nodules on portal venous, delayed, or 
transitional phases. The term, capsule appearance or “cap-
sule,” is preferred because its visualization does not always 
 correlate with a pathologically identified true capsule.31,32 The 
degree of enhancement typically increases from early to later 
phases, reflecting the slow flow of intracapsular vessels. If 
a “capsule” is nonenhancing or visible only on unenhanced 
images, it is considered an ancillary feature “favoring HCC 
in particular,” rather than a major LI-RADS feature.16 The 
capsule appearance is not to be confused with “corona 
enhancement” defined as periobservational enhancement in 
the late arterial phase or early portal venous phase. Corona 
enhancement is an ancillary feature favoring malignancy (but 
not specific for HCC).15
Observation size
As the shape of observations may be ovoid or irregular, the 
term size was adopted instead of diameter, which by defini-
tion, applies only to circles or spheres.27 Size is defined as 
the largest outer-edge-to-outer-edge dimension of an observa-
tion, including the capsule if present.15 Accurate measurement 
of observation size is important as it influences the staging of 
HCC and plays a role in determining transplant eligibility.33 
It is also used for the assessment of threshold growth during 
follow-up imaging. The reader should measure observation 
size on the phase or sequence in which the margins are 
clearest. However, measurement during the arterial phase 
or diffusion-weighted imaging should be avoided because 
arterial phase measurement may overestimate size due to 
differences in timing of the arterial phase between scans 
or inadvertent inclusion of corona enhancement and the 
diffusion-weighted images tend to have anatomic distortion, 
which can affect measurements.16
Threshold growth
The definition of threshold growth was revised for v2018 to 
be consistent with definitions endorsed by OPTN. It is now 
defined as ≥50% increase in size of a mass in ≤6 months.16 
An unequivocal increase in size that does not meet the defini-
tion of “threshold growth” is considered an ancillary feature 
“favoring malignancy in general, not HCC in particular.”16 
Caution is required when applying growth as a diagnostic 
criterion for HCC, as other malignant neoplasms (eg, iCCA 
and cHCC-CCA) can grow.25
Ancillary imaging features used in 
CT/MRI LI-RADS
Unlike the major features, the incorporation of ancillary 
imaging features, which are additional supportive features 
favoring malignancy or benignity, into the final category 
Figure 6 Seventy-one-year-old female demonstrating nonrim arterial phase 
hyperenhancement.
Notes: Contrast-enhanced CT shows a large mass (arrows) in the left hepatic lobe, 
partially exophytic, demonstrating heterogeneous arterial phase hyperenhancement. 
Posthepatectomy pathology confirmed well-differentiated hepatocellular carcinoma.
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assignment is considered optional.15 It is up to the radiolo-
gist’s clinical judgment to use these features to upgrade or 
downgrade an observation to refine the final category.34 
Ancillary features can be used to upgrade (only up to LR-4) 
or downgrade an observation by one category only, regard-
less of how many ancillary features exist. However, ancillary 
features cannot upgrade an observation from LR-4 to LR-5 as 
these ancillary features do not currently have a high enough 
specificity for diagnosing HCC.15,27 Ancillary features are 
divided into three groups; 1) features favoring malignancy 
in general, 2) features favoring HCC in particular, and 3) 
features favoring benignity.15,34 If the features are conflicting, 
ie, demonstrating a mix of features favoring both malignancy 
and benignity, then the category should stay the same with-
out change.27 Definitions of ancillary features are shown in 
Figure 7 and have not changed from v2017. Of note, these 
ancillary features apply to CT/MRI categorization and not 
to CEUS as there are different distinct features related to 
CEUS discussed later.
CT/MRI LI-RADS categories
CT/MRi LR-1 to LR-5
These represent the LI-RADS categories assigned to obser-
vations based on the probability of benignity vs malignancy 
determined by the presence of major and ancillary imaging 
features.15 LR-1 to LR-5 categories serve as a probabilistic 
scale that reflects the probability of benignity, malignancy 
in general, or HCC.
CT/MRi LR-NC
LR-NC is applied when there are considerable technical 
limitations to the image quality and therefore, assigning an 
LI-RADS category is not feasible. Based on the LI-RADS 
management algorithm, the radiologist may recommend 
repeat imaging at ≤3 months if the cause of the technical 
limitation is resolvable or switch to an alternative imag-
ing modality otherwise (eg, switching to CT from MRI if 
blooming artifact from an embolization coil obscures much 
of the liver).15,27
CT/MRI LR-TIV (definitely malignant with 
Tiv)
LR-TIV is assigned when definite tumor invasion of a vein 
is observed regardless of whether there is an associated 
parenchymal mass. Although TIV is usually due to HCC, it 
can be caused by non-HCC malignancies such as iCCA and 
combined HCC-CCA tumors.15,27
CT/MRI LR-M (malignancy not specific to 
HCC)
This is assigned to probably or definitely malignant obser-
vations that do not meet the criteria for diagnosis of HCC. 
Figure 7 Ancillary imaging features used in Li-RADS CT/MRi.
Note: These ancillary features are supportive, and their use is optional. Reproduced with permission from American College of Radiology. Liver imaging Reporting and Data 
System version 2018 core. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Li-RADS.16
Abbreviations: ACR, American College of Radiology; HCC, hepatocellular carcinoma; Li-RADS, Liver imaging Reporting and Data System; US, ultrasound.
Ancillary features favoring malignancy
Favoring malignancy in general, not HCC in
particular
• US visibility as discrete nodule
• Subthreshold growth
• Restricted diffusion
• Mild–moderate T2 hyperintensity
• Corona enhancement
• Fat sparing in solid mass
• Iron sparing in solid mass
• Transitional phase hypointensity
• Hepatobiliary phase hypointensity
Favoring HCC in particular
• Nonenhancing "capsule"
• Nodule-in-nodule
• Mosaic architecture
• Blood products in mass
• Fat in mass, more than adjacent liver
Ancillary features favoring benignity
• Size stability > 2 years
• Size reduction
• Parallels blood pool
• Undistorted vessels
• Iron in mass, more than liver
• Marked T2 hyperintensity
• Hepatobiliary phase isointensity
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These lesions have a broad differential diagnosis that 
includes not only HCC but also metastases, iCCA, or com-
bined tumors.15,35 This category was devised to preserve the 
specificity of the LR-5 category without loss of sensitivity 
for detection of malignancy.
Assigning LI-RADS diagnostic 
category using CT/MRI
Prior to applying the LI-RADS diagnostic algorithm, the 
radiologist should ensure the patient is at increased risk of 
developing HCC (as described above in LI-RADS diagnostic 
population). Selectively applying LI-RADS algorithms to 
at-risk populations is important in avoiding diagnostic errors 
and maintaining the high specificity of the LR-5 category.5 
LR-5 (definitely HCC) carries a nearly 100% specificity 
for HCC, which eliminates the need for histopathological 
confirmation. The diagnostic algorithm also should not be 
applied to focal observations after locoregional therapy; the 
treatment response algorithm should be applied instead.36 
After these initial checks, a simplified four-step approach to 
assigning LI-RADS categories can be performed, which is 
unchanged in v2018.15
Step 1: Apply CT/MRi Li-RADS diagnostic 
algorithm
First, the interpreting radiologist should examine the study 
for quality and completeness in terms of necessary dynamic 
enhancement phases to assess whether assigning a diagnostic 
category is feasible.5,15,27 If key imaging phases are miss-
ing or obscured by artifact, then the observation should be 
assigned LR-NC.
Once the quality and completeness of the study is con-
firmed, the liver should be evaluated for the presence of TIV 
(Figure 8). If present, LR-TIV category should be assigned 
regardless of the visualization of a parenchymal observation. 
The reporting of LR-TIV should reflect the possible etiologies 
of the venous invasion as follows: 1) if TIV is contiguous 
with a targetoid parenchymal mass, report: “LR-TIV, may 
be due to non-HCC malignancy”; 2) if TIV is contiguous 
with an observation meeting LR-5 criteria, report: “LR-TIV, 
definitely due to HCC”; and 3) in all other scenarios, report: 
“LR-TIV, probably due to HCC.”5
After excluding the presence of TIV, the radiologist 
should consider the features of individual observations and 
determine if they are definitely (LR-1) or probably (LR-2) 
benign.15 Definitely benign observations (LR-1) include hem-
angiomas, cysts, confluent fibrosis, and focal fat  deposition 
or sparing. Probably benign observations (LR-2) have high 
but not 100% probability of benignity, such as  probable 
hemangioma, probable perfusion alterations, and <20 mm 
distinctive nodules with no major or ancillary features favor-
ing malignancy.37,38
If an observation does not meet the criteria for LR-1 or 
LR-2, then it should be determined if it meets the criteria 
for LR-M (Figure 9). LR-M is assigned to solid observation 
with a targetoid appearance (Figure 9) or with one or more 
of the following imaging features: infiltrative appearance, 
marked diffusion restriction, necrosis, or severe ischemia.5,35
If all the categories above are excluded after stepwise 
consideration, the LI-RADS CT/MRI diagnostic table 
(Figure 1) is applied and the observation is assigned a 
category LR-3, LR-4, or LR-5 based on the presence of 
major features.16 First, the observation should be assessed 
for the presence of nonrim APHE. Second, the size of the 
observation is measured to determine the correct column 
in the table.5,16,27 Observations without APHE are separated 
into <20 mm or ≥20 mm, while observations with nonrim 
APHE are divided into <10 mm, 10–19 mm, and ≥20 mm. 
Note that LR-5 category is reserved for observations, 
which are both 10 mm or larger and demonstrate nonrim 
APHE. Finally, the number of major features present 
other than nonrim APHE is assessed to determine the 
appropriate row in the table.5,16 The cell at the intersection 
between the selected column and row contains the correct 
LI-RADS category.
Step 2: Apply ancillary features
After assigning the initial LI-RADS category, the radiologist 
may elect to apply ancillary features to adjust the category 
as explained previously.5,34
Step 3: Apply tiebreaking rules
If, after following the algorithm through the first two steps, 
there is still uncertainty between two categories (often due to 
uncertainty regarding the presence of one or more imaging 
features), the radiologist should then choose the category 
associated with lower diagnostic certainty.16,27 For example, 
if the radiologist is uncertain regarding the presence of TIV, 
then LR-TIV should not be assigned.
Step 4: Perform a final check
Finally, the radiologist should consider whether the assigned 
category seems appropriate based on their clinical judgment. 
If it is appropriate, then the category is finalized, and the 
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Figure 8 Fifty-eight-year-old man with cirrhosis (AFP=285 ng/mL) tumor in vein (Tiv), probably due to hepatocellular carcinoma.
Notes: Gadobenate dimeglumine-enhanced MRi shows unequivocal enhancement of tissue (arrow) within the left portal vein, which meets the criterion for LR-Tiv. Notice 
that the tissue expands the lumen of the left portal vein, (A) hyperenhances in the arterial phase, (B) appears to washout in the portal venous phase and has high signal 
intensity on (C) T2-weighted and (D) diffusion-weighted images. involvement of the parenchyma by the tumor is more conspicuous on diffusion-weighted images (arrow-
head in D).
A B
C D
radiologist should move on to the next observation. If not, 
then the radiologist should reevaluate. Consultation with a 
colleague for a second opinion may be reasonable if doubt 
persists.5
CEUS LI-RADS
CeUS Li-RADS diagnostic categories
The diagnostic categories of CEUS (Figure 10) follow the 
same general template of CT/MRI with some modifications 
to the criteria required to assign these categories.39
CeUS LR-NC
This category is usually assigned to observations where 
significant limitations of the technique or poor quality of 
the study due to external factors such as large body habitus 
would prevent assigning an appropriate category to the 
observation.39,40
CeUS LR-Tiv
This is assigned when there is unequivocal visualization of 
enhancing soft tissue in vein, regardless of visualization of 
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parenchymal mass (Figure 11). CEUS is particularly helpful 
in differentiation between TIV and bland thrombus depend-
ing on the time of microbubble contrast agent arrival to the 
vein, where early arrival (same as hepatic artery) favors TIV 
and arrival several seconds after hepatic artery enhancement 
would favor recanalized/nonocclusive bland thrombus.39
Figure 9 Sixty-one-year-old man with chronic hepatitis C and cirrhosis.
Notes: A 2 cm observation in hepatic segment 5 shows (A) rim arterial phase hyperenhancement, (B) progressive delayed central enhancement on portal venous, and (C) 
delayed phase, corresponding to a targetoid appearance (LR-M). Biopsy confirmed intrahepatic cholangiocarcinoma. Arrow shows the enhancement pattern.
A B C
Figure 10 Diagnostic categories for CeUS Li-RADS.
Notes: Reproduced with permission from American College of Radiology. CeUS Li-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-
Data-Systems/Li-RADS/CeUS-Li-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; CeUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; Li-RADS, Liver imaging Reporting and Data 
System; LR-NC, LR-noncategorizable; Tiv, tumor in vein.
CEUS LR-NC
Not categorizable
(due to image degradation
or omission)
Definitely benign
Probably benign
Probably HCC
Intermediate probability
of malignancy
Definitely HCC
TIV
Probably or definitely malignant,
not necessarily HCC
Diagnostic
categories
CEUS LR-1
CEUS LR-2
CEUS LR-3
CEUS LR-4
CEUS LR-5
CEUS LR-M
CEUS LR-TIV
CEUS LI-RADS® 2017 Categories
 
Jo
ur
na
l o
f H
ep
at
oc
el
lu
la
r 
C
ar
ci
no
m
a 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
04
-O
ct
-2
01
9
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Hepatocellular Carcinoma 2019:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
60
elsayes et al
CeUS LR-M
This category is assigned to a probably or definitely malignant 
nodule, not particularly an HCC. The criteria for inclusion 
into LR-M are shown in Figure 12.
CeUS LR-1 to LR-5
These are the same categories as CT/MRI LI-RADS and are 
assigned based on the probability of the observation being 
benign (LR-1 and LR-2) or malignant (LR-3, LR-4, and 
Figure 11 CeUS Li-RADS Tiv.
Notes: (A) Soft tissue in the portal vein (arrows) contiguous with a parenchymal mass (star) on B-mode ultrasound. (B, C) Both soft tissue within the portal vein (arrows) 
and the mass (star) show arterial phase hyperenhancement and (D) mild washout in the late phase. CeUS Li-RADS Tiv Criteria:
•  Unequivocal arterial phase hyperenhancement and washout of soft tissue within the lumen of portal and/or hepatic veins.
• Must correspond on dual screen with mass in vein.
• Most LR-TIVs are HCC. Some are iCCA or cHCC-CCA.
• CEUS has been shown to have high sensitivity and specificity to diagnose TIV.
Abbreviations: CeUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; Tiv, tumor in vein.
A B
C D
B mode 19 s
23 s 9 m
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LR-5). The major difference lies in the number of major and 
ancillary features used to assign categories LR-3 to LR-5.39
Major imaging features used in 
CEUS LI-RADS
Nonrim APHe
Similar to CT/MRI, nonrim APHE is one of the major fea-
tures for CEUS LI-RADS and is considered present if dem-
onstrated in either the entirety or just a portion of the nodule. 
In contrast to CT/MRI, CEUS or grayscale ultrasound does 
not visualize arterioportal shunts.40 Thus, in contradistinc-
tion to CT and MRI, most observations detectable by CEUS 
are true nodules, and the presence of nonrim APHE by itself 
prompts LR-4 categorization, regardless of nodule size. Of 
note, if the APHE on CEUS is peripheral, discontinuous, and 
globular, this is characteristic of a hemangioma.39
washout
CEUS uses purely intravascular microbubble contrast agents, 
which makes CEUS washout a true washout and does not 
require using the terms washout appearance or “washout.”39 
CEUS may be used to differentiate between typical HCC 
and other malignant lesions that show APHE by assessment 
of the onset (late vs early) and degree (mild vs marked) of 
washout. Early-onset washout is considered present when 
detected within 60 seconds of contrast agent injection, while 
late-onset washout is characterized when detected at or after 
the 60-second mark (Figure 13A).40 Marked washout is con-
sidered present when the nodule is mostly devoid of contrast 
and is seen as “punched out” within 2 minutes after contrast 
injection (Figure 13B). Marked washout is one of the charac-
teristics of LR-M category. Mild washout, however, is defined 
as a nodule demonstrating less degree of enhancement than 
the surrounding liver parenchyma but still possessing some 
degree of contrast enhancement.40 Nodules with mild washout 
may later appear as showing marked washout. Thus, if this 
occurred after 2 minutes, it should still be categorized as 
mild washout. HCCs usually show late-onset mild washout 
in contrast to non-HCC malignancies that demonstrate early-
onset and/or marked washout (Figure 13C).39
Ancillary imaging features used in CeUS 
Li-RADS
Ancillary features are applied less often in CEUS com-
pared with CT/MRI. Similar to CT/MRI, they can be used 
to upgrade or downgrade the category of an observation; 
similarly, they cannot be used to upgrade LR-4 to LR-5.39 
One advantage of CEUS over CT/MRI is the fewer number 
of ancillary features, which reduces the interpretive burden 
on the radiologist. Definitions of these features are shown 
in Figure 14. They are also divided into three categories, 
analogous to those used in CT and MRI.39
Assigning Li-RADS diagnostic category 
using CeUS
CEUS is used similar to contrast-enhanced CT and MRI for 
dynamic evaluation of lesions as well as surrounding blood 
flow in the form of APHE and washout.39,40 Limitations of 
CEUS are that it cannot be used for staging the entire liver, 
and it has not been validated for the assessment of treatment 
response.39,41 The population in which CEUS LI-RADS can 
be applied is the same as that of CT/MRI. CEUS is indi-
cated for the characterization of observations ≥10 mm when 
detected on a surveillance ultrasound. It can also be used to 
detect APHE when evaluation with CT or MRI is not possible 
(or technically suboptimal). CEUS can be used to evaluate 
previously biopsied observations with inconclusive histol-
ogy and to differentiate between TIV and bland thrombus.39 
Although the key concepts and principles of CEUS catego-
ries (Figure 10) appear similar to those of CT/MRI, there 
are important differences that warrant separate diagnostic 
features and characterization algorithms.39,40
Figure 12 CeUS Li-RADS M criteria.
Notes: Reproduced with permission from American College of Radiology. CeUS Li-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-
Data-Systems/Li-RADS/CeUS-Li-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; CeUS, contrast-enhanced ultrasound; Li-RADS, Liver imaging Reporting and Data System.
CEUS LI-RADS M criteria. 
Distinct solid nodule with at least some enhancement in the arterial phase (regardless of
morphological pattern of degree) with either or both of the following:  
• 
• 
• 
• 
• 
Early (<60s) washout relative to liver 
Marked washout resulting in a "punched out" appearance within 2 minutes of
contrast injection
OR
Arterial phase rim enhancement, followed by washout (regardless of onset or degree)
Multidisciplinary discussion for tailored work up is recommended. Often includes biopsy. 
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Figure 14 AFs used in CeUS Li-RADS.
Notes: Reproduced with permission from American College of Radiology. CeUS Li-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-
Data-Systems/Li-RADS/CeUS-Li-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; AF, ancillary feature; CeUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; Li-RADS, Liver imaging 
Reporting and Data System.
Ancillary features.
CEUS AFs favoring malignancy CEUS AFs favoring benignity
Favoring malignancy in general, not HCC in
particular
• Definite growth
Favoring HCC in particular
• Nodule-in-nodule architecture 
• Mosaic architecture
• Size stability ≥ 2 years
• Size reduction
If unsure about presence of any ancillary feature: characterize that feature as absent
Figure 13 washout.
Notes: (A) early weak washout seen within 1 minute after contrast injection (CeUS LR-M feature). (B) Marked washout seen within 2 minutes after contrast injection (CeUS 
LR-M feature). (C) Late and mild washout seen >1 minute after contrast injection (CeUS LR-5 feature).
Abbreviation: CeUS, contrast-enhanced ultrasound.
A B
C
46 s 1 m
5 m
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Step 1: Apply the CeUS Li-RADS 
diagnostic algorithm
The steps to apply CEUS diagnostic algorithm (Figure 15) 
follow closely those of CT/MRI. Below a few distinctions 
are highlighted.
If a definitely benign lesion is eliminated from consid-
eration, then an observation can be categorized as probably 
benign (LR-2) based on the following criteria; 1) distinct 
isoenhancing solid nodule <10 mm, 2) nonmass-like isoen-
hancing observation of any size while not being of typical 
fatty change/sparing appearance, and 3) LR-3 nodules with 
interval stability for at least 2 years. If an observation does not 
meet the LR-1 or LR-2 criteria, then it should be evaluated for 
the presence of LR-M criteria (Figure 12). On CEUS, these 
criteria include 1) early washout relative to background liver 
within 60 seconds of the contrast agent injection, 2) marked 
washout resulting in a punched-out appearance within 2 
minutes of contrast agent injection, and 3) rim APHE fol-
lowed by washout.
After exclusion of LR-M, CEUS LI-RADS diagnostic 
table should be applied and categories LR-3, LR-4, or LR-5 
should be assigned to the observation based on size and the 
presence of major features. LR-4 category is assigned to 
observations that have high but not 100% probability of HCC. 
LR-5 category is only assigned to observations at least 10 mm 
or larger with nonrim APHE and mild late-onset washout. The 
CEUS diagnostic table is similar to the CT/MRI diagnostic 
table. One exception is that greater emphasis is placed on 
nonrim APHE because any observation with nonrim APHE 
is an arterialized nodule as described earlier. Another excep-
tion is that the characterization of washout is based on its 
timing and degree, not just on its presence. Figures 15–17 
Figure 15 CeUS Li-RADS diagnostic algorithm and table.
Notes: Reproduced with permission from American College of Radiology. CeUS Li-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-
Data-Systems/Li-RADS/CeUS-Li-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; APHe, arterial phase hyperenhancement; CeUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; Li-
RADS, Liver imaging Reporting and Data System; ; LR-NC, LR-noncategorizable; Tiv, tumor in vein; US, ultrasound.
CEUS LR-NC
CEUS LR-1
CEUS LR-2
CEUS LR-M
CEUS LR-TIV
CEUS LR-4
CEUS LR-4
CEUS LR-3
CEUS LR-5
CEUS LR-5
CEUS LR-3
CEUS LR-4
CEUS LR-3
CEUS LR-4
CEUS LR-3
≥10<10≥20<20
No APHE APHE **
** APHE:
* CEUS LR-M criteria:
●  Rim APHE OR
●  Early (<60s) washout OR
●  Marked washout
●  Not rim (indicates LR-M)
●  Not peripheral discontinuous globular (indicates hemangioma)
CEUS LR-3
No washout of any type
Nodule size (mm)
If intermendiate malignancy probablility
Probably or definitely malignant, not specific for HCC*
If probably but not definitely benign
If definitely benign
If TIV
If cannot be categorized due to image degradation or omission
Untreated observation visible on pre-contrast US and
without pathologic proof in patients at high risk for HCC
Otherwise, use CEUS diagnostic table below
If probably HCC
If definitely HCC
APHE
CEUS diagnostic table
Late and mild washout
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Figure 16 CeUS LR-5.
Notes: (A) A 17 mm hypoechoic nodule on B-mode ultrasound. (B) The entire nodule shows hyperenhancement in the arterial phase. (C) At 1 minute, the nodule is 
isoenhancing compared with the surrounding liver parenchyma. (D) The nodule shows mild but definite hypoenhancement compared with the surrounding liver parenchyma 
at 2 minutes. This is late and mild washout. Arrows show the outline of the nodule.
Abbreviation: CeUS, contrast-enhanced ultrasound.
A B
C D
B mode 18 s
1 m 2 m
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Figure 17 CeUS LR-4.
Notes: (A) A 12 mm hypoechoic nodule on B-mode ultrasound. (B) The entire nodule shows hyperenhancement in the arterial phase. (C) At 2 minutes, the nodule is 
isoenhancing compared with the surrounding liver parenchyma. (D) The nodule remains isoenhancing at 5.5 minutes without washout. Arrows show to the outline of the 
nodule.
Abbreviation: CeUS, contrast-enhanced ultrasound.
A B
C D
B mode 11 s
2 m 5.5 m
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Figure 18 CeUS Li-RADS AFs upgrade and downgrade of categories.
Notes: Reproduced with permission from American College of Radiology. CeUS Li-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-
Data-Systems/Li-RADS/CeUS-Li-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; AF, ancillary feature; CeUS, contrast-enhanced ultrasound; Li-RADS, Liver imaging Reporting and Data System.
CEUS LR-4 CEUS LR-5CEUS LR-3
Probably HCC
≥ 1 AF favoring malignancy: upgrade by 1 category up to LR-4
(absence of these AFs should not be used to downgrade)
≥ 1 AF favoring benignity: downgrade by 1 category
CEUS LR-2CEUS LR-1
Figure 19 CeUS Li-RADS tiebreaking rules.
Notes: Reproduced with permission from American College of Radiology. CeUS Li-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-
Data-Systems/Li-RADS/CeUS-Li-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; CeUS, contrast-enhanced ultrasound; Li-RADS, Liver imaging Reporting and Data System; Tiv, tumor in vein.
Lower certainly of
benignity
Lower certainly of
malignancy
Lower certainly of
hepatocellular
origin
CEUS
LR-4
CEUS LR-M
CEUS
LR-TIV
CEUS
LR-5
CEUS
LR-3
No TIV
If unsure about presence of TIV, do not categorize as CEUS LR-TIV
If unsure between two categories, choose the one reflecting lower certainty
CEUS
LR-2
CEUS
LR-1
show examples of different nodules with CEUS categories 
assigned to them.
Steps 2 (apply ancillary features) (Figure 18), 3 (apply 
tiebreaking rules) (Figure 19), and 4 (final check) are con-
ceptually identical to their CT/MRI counterparts.39
LI-RADS treatment response
Li-RADS treatment response categories
The LI-RADS treatment response algorithm was introduced 
in v2017 to guide interpretation of response following 
locoregional therapy and to improve clarity and consistency 
of communication between multidisciplinary teams manag-
ing HCC patients.27
Response evaluation criteria in solid tumors and modi-
fied response evaluation criteria in solid tumor serve as the 
standard criteria for assessing treatment response in  oncology 
clinical trials; however, these systems are not designed for 
use in routine practice and do not currently contribute to 
OPTN staging for organ allocation in liver transplantation. 
The LI-RADS treatment response algorithm and categories 
apply to observations treated by a range of locoregional 
therapies, but do not apply to systemic treatment response; 
the system can be used with caution in patients undergoing 
both locoregional and systemic therapy when the locoregional 
treatment effects are dominant.36 The treatment response 
algorithm defines specific imaging features/criteria for 
individual response categories, which are intended to com-
municate the probability of residual viable tumor following 
therapy. It is worth mentioning that these criteria primarily 
reflect vascularization of tissues as a surrogate for viability; 
this does not necessarily translate to complete pathological 
response due to the inability of imaging to detect microscopic 
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foci of residual tumor.36,42 The categories and their definitions 
are listed below and provided in Figure 20.
LR-TR nonevaluable
This category is assigned when the treatment response 
cannot be evaluated due to poor image quality, inadequate 
technique, or time interval after therapy too soon for reliable 
interpretation.36
LR-TR nonviable
The nonviable category should be assigned to treated lesions 
with no appreciable enhancement or to lesions demonstrating 
expected posttreatment enhancement patterns.16 For example, 
a common expected posttreatment enhancement pattern 
is thin rim enhancement that becomes progressively more 
intense on postarterial phases.
LR-TR viable
The viable category should be assigned to treated lesions with 
nodular, mass-like, or thick irregular regions of APHE, wash-
out appearance, or enhancement similar to pretreatment.36
LR-TR equivocal
This category is applied to lesions that cannot be clearly cat-
egorized as viable or nonviable due to atypical  enhancement 
patterns in the absence of technical or patient-related 
limitations.27
Assigning Li-RADS treatment response 
categories using CT/MRi
Similar to the diagnostic systems, the treatment response 
assessment is done in four steps.27
Step 1: Apply Li-RADS CT/MRi treatment 
response algorithm
First, the reader should confirm that the imaging study is 
adequate, ie, without significant degradation or omission 
of required images. If the required images are not present, 
then category LR-TR nonevaluable should be assigned.36 If 
treatment response can be evaluated, then one of the three 
LR-TR categories should be assigned.
Step 2: Measure observation size
LR-TR viable and LR-TR equivocal lesions should be mea-
sured. The region of viable or potentially viable tumor is 
measured as the longest dimension of the enhancing tissue, 
without traversing the nonenhancing area. This one-dimen-
sional measurement serves as the observation size when 
reporting LR-TR viable or LR-TR equivocal lesions.27 When 
Figure 20 Treatment response categories with examples from a 70-year-old man who underwent transarterial radioembolization (Y90) followed by transarterial bland 
embolization and microwave ablation (MwA).
Notes: Left column shows no evidence of enhancement after MWA, categorized as LR-TR nonviable. Center column shows ill-defined enhancement (arrows) 5 months 
after Y90, categorized as LR-TR equivocal. Right column shows mass-like arterial phase hyperenhancement in the treated lesion (arrowheads), categorized as LR-TR viable.
LR-TR nonviable LR-TR equivocal LR-TR viable
LR-TR nonevaluable
4 months post MWA
If able to evaluate
treatment response,
assign one category
Treated
observation
If unable to evaluate
treatment response
Ar
te
ria
l
Po
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5 months post Y90 10 months post Y90
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present, the size of residual viable tumor helps dictate man-
agement decisions and track tumor burden, eg, while awaiting 
transplantation. If there is no lesional enhancement or the 
enhancement pattern is expected for the applied therapy, then 
the appropriate treatment category is LR-TR nonviable; in 
this context, the size of viable tumor has no meaning and a 
size measurement does not need to be reported.15
Steps 3 and 4: Apply tiebreaking rule and 
perform final check
If the radiologist is undecided on the posttreatment category, 
LR-TR equivocal should be chosen to reflect the lower 
certainty of residual tumor. As a final check, the radiologist 
should question the assigned category and reevaluate if that 
category is inappropriate.15 CT/MRI diagnostic categories 
should still be used for untreated lesions or new lesions 
developing elsewhere in the liver.
Conclusion
LI-RADS has been created as a dynamic system with regular 
updates to maintain best practices based on latest evidence 
and expert multidisciplinary consensus. LI-RADS has been 
refined and expanded over multiple updates to now also 
address ultrasound-based surveillance, CEUS for HCC 
diagnosis, and CT/MRI for assessing treatment response after 
locoregional therapy in addition to CT/MRI diagnosis. LI-
RADS is consistent with the National Comprehensive Cancer 
Network (NCCN) guidelines and can be easily converted to 
OPTN classes for liver transplant evaluation. The new ver-
sion of LI-RADS is now fully integrated into the AASLD 
2018 HCC clinical practice guidance, which represents a 
major step toward widespread endorsement of LI-RADS in 
clinical practice.
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